Skip to content

Contact +44 (0) 20 7060 7474 email us

Johnson & Johnson

Johnson & Johnson: PharmaVitae Profile

Healthcare

Publication Date July 2009
Publisher Datamonitor
Product Type Report
Pages 108
ISBN Number not applicable
Product Code DAT00602

Price

£3,765.00
approximately: $5,701 | €4,202

pdf

Buy Now

print £3,830 ($5,799 | €4,275)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Johnson & Johnson's performance against key rivals in the prescription pharmaceutical sector
  • Analyze how J&J will implement life cycle management strategies across its portfolio as a means to combat patent expiries and generic competition
  • Assess J&J's diverse healthcare offering and how this will act to maintain operating profit growth despite a forecast decline in Rx drug revenue

Contents

  • ABOUT DATAMONITOR HEALTHCARE
  • About the PharmaVitae team
  • Chapter 1 About this profile
    • PharmaVitae Explorer database
  • Chapter structure
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • Chapter 2 Executive summary
    • Key findings
    • Prescription pharmaceutical sales and growth rate performance, 2002-14
    • Financial performance, 2002-14
    • Johnson & Johnson: PharmaVitae forecasts at a glance
    • Strategic insight
    • Managing the boom & bust of 'blockbuster' drugs
    • US small molecule drug sales increase generic exposure
    • Lifecycle management will minimize loss from key products
    • Pipelines in a product-critical for growth to be maintained
    • Despite challenges, J&J's outlook appears robust
    • Performance to 2014 will be clear by 2010
    • Diversified business balances risk
    • Wide range of strategic options to seek growth
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • Table of figures
  • Chapter 3 Quarterly news update
    • Key findings
    • Product developments
    • Deals and alliances
    • Product deals
    • Technology deals
    • M&A activity
    • Company announcements
    • Future product milestones
  • Chapter 4 Company introduction
    • Key findings
    • Background
    • Key corporate developments
    • M&A history
    • M&A strategy
    • Current corporate structure
  • Chapter 5 Company sales
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2002-14
    • Product analysis
    • Product analysis, 2002-08
    • Product analysis, 2008-14
    • Therapy area analysis
    • Geographic analysis
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2008-14
    • Core analysis, 2008-14
    • Expiry analysis, 2008-14
    • Generics analysis, 2008-14
    • Molecule type analysis
    • Externalization analysis
  • Chapter 6 Company financials
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
    • Operating costs and profit analysis
    • Operating costs and profit analysis, 2002-08
    • Operating cost ratio and profit margin analysis, 2002-08
    • Operating cost ratio and profit margin analysis, 2008-14
    • Operating costs and profit analysis, 2008-14
  • Chapter 7 Key products and competitors
    • Key findings
    • Overview
    • Central nervous system
    • Risperdal franchise
    • Overview
    • Sales forecast
    • Success driven by first to market and favorable side effect profile
    • US generics hit Risperdal sales from June 2008
    • Additional products aimed at retaining patients within JNJ's portfolio
    • Invega franchise
    • Overview
    • Sales forecast
    • Limited switching from Risperdal
    • Invega Sustenna will build upon Risperdal Consta's success
    • Topamax
    • Overview
    • Sales forecast
    • Sales growth has been supported by use in further indications
    • Generics set to erode key US market across 2008-09
    • Immunology & inflammation
    • Remicade
    • Overview
    • Sales forecast
    • J&J markets Remicade in the US only
    • Humira has slowed growth of Remicade sales
    • New launches will maintain the growth of J&J's I&I franchise
    • Simponi (golimumab)
    • Overview
    • Sales forecast
    • Stelara (ustekinumab)
    • Overview
    • Sales forecast
    • Oncology
    • Velcade
    • Overview
    • Sales forecast
    • Growth driven by label expansion
    • Takeda prevented J&J from acquiring Millennium
    • Procrit
    • Overview
    • Sales forecast
    • Decline as market share lost to Aranesp from 2002
    • Safety concerns have hit the wider ESA market
    • Further competition limited to ex-US markets for now
    • Cardiovascular
    • Xarelto
    • Overview
    • Sales forecast
    • US launch forecast in 2009
    • Set to revolutionize anticoagulant management
    • Attractive product profile ensures market success
    • Regulatory hurdles remain
    • Infectious diseases
    • Prezista
    • Overview
    • Sales forecast
    • Growth strengthened by earlier use
    • Close fit with additional HIV products
  • Chapter 8 Appendix
    • R&D pipeline
    • Remicade sales reconciliation
    • References
    • Abbreviations
    • Exchange rates
    • About Datamonitor
    • About Datamonitor Healthcare
    • Datamonitor consulting
    • Disclaimer
    • Table 1: Johnson & Johnson - PharmaVitae forecasts at a glance
    • Table 2: Johnson & Johnson key product developments, Q1-Q2 2009
    • Table 3: Johnson & Johnson product deals and alliances, Q1-Q2 2009
    • Table 4: Johnson & Johnson technology deals and alliances, Q1-Q2 2009
    • Table 5: Johnson & Johnson M&A activity, Q1-Q2 2009
    • Table 6: Johnson & Johnson company announcements, Q1-Q2 2009
    • Table 7: Johnson & Johnson future product milestones, 2009-10
    • Table 8: Johnson & Johnson product portfolio overview ($m), 2002-08
    • Table 9: Johnson & Johnson product portfolio overview ($m), 2008-14
    • Table 10: Johnson & Johnson prescription pharmaceutical sales by therapy area ($m), 2008-14
    • Table 11: Johnson & Johnson prescription pharmaceutical sales by geographic region ($m), 2008-14
    • Table 12: Johnson & Johnson launch portfolio overview ($m), 2008-14
    • Table 13: Johnson & Johnson core portfolio overview ($m), 2008-14
    • Table 14: Johnson & Johnson expiry portfolio overview ($m), 2008-14
    • Table 15: Johnson & Johnson generics portfolio overview ($m), 2008-14
    • Table 16: Johnson & Johnson prescription pharmaceutical sales by molecule type ($m), 2008-14
    • Table 17: Johnson & Johnson prescription pharmaceutical sales by source ($m), 2008-14
    • Table 18: Total Johnson & Johnson sales by business unit ($m), 2002-08
    • Table 19: Johnson & Johnson operating revenue/cost analysis ($m), 2002-08
    • Table 20: Johnson & Johnson operating cost ratio analysis (% of total revenues), 2002-08
    • Table 21: Johnson & Johnson operating cost ratio analysis (% of total revenues), 2008-14
    • Table 22: Johnson & Johnson operating revenue/cost analysis ($m), 2008-14
    • Table 23: Key products overview
    • Table 24: Risperdal: overview
    • Table 25: Risperdal franchise: sales forecast ($m), 2008-14
    • Table 26: Invega: overview
    • Table 27: Invega franchise: sales forecast ($m), 2008-14
    • Table 28: Topamax: overview
    • Table 29: Topamax: sales forecast ($m), 2008-14
    • Table 30: Remicade: overview
    • Table 31: Remicade: sales forecast ($m), 2008-14
    • Table 32: Simponi: overview
    • Table 33: Simponi: sales forecast ($m), 2008-14
    • Table 34: Stelara: overview
    • Table 35: Stelara: sales forecast ($m), 2008-14
    • Table 36: Velcade: overview
    • Table 37: Velcade: sales forecast ($m), 2008-14
    • Table 38: Procrit: overview
    • Table 39: Procrit: sales forecast ($m), 2008-14
    • Table 40: Xarelto: overview
    • Table 41: Xarelto: sales forecast ($m), 2008-14
    • Table 42: Prezista: overview
    • Table 43: Prezista: sales forecast ($m), 2008-14
    • Table 44: Johnson & Johnson's R&D pipeline (Phase I-registration)
    • Table 45: Total Remicade sales forecast ($m), 2008-14
    • Table 46: Exchange rates, 2009
  • List of Figures
    • Figure 1: The PharmaVitae Explorer
    • Figure 2: Johnson & Johnson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
    • Figure 3: Johnson & Johnson's financial performance ($m), 2002-14
    • Figure 4: Lifecycle management strategies boost key J&J franchises, 2002-14 ($m)
    • Figure 5: Johnson & Johnson prescription pharmaceutical sales by stage, 2002-14 ($m)
    • Figure 6: J&J's strategic options for growth
    • Figure 7: Johnson & Johnson SWOT analysis
    • Figure 8: Recent & major M&A/ divestment activity, J&J
    • Figure 9: Current corporate structure
    • Figure 10: Johnson & Johnson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
    • Figure 11: Key product sales ($m), 2002-14
    • Figure 12: Johnson & Johnson key sales growth drivers and resistors ($m), 2002-08
    • Figure 13: Johnson & Johnson key sales growth drivers and resistors ($m), 2008-14
    • Figure 14: Johnson & Johnson prescription pharmaceutical sales by therapy area ($m), 2002-14
    • Figure 15: Johnson & Johnson prescription pharmaceutical sales by geographic region ($m), 2002-14
    • Figure 16: Johnson & Johnson launch/core/expiry configuration ($m), 2008-14
    • Figure 17: Johnson & Johnson prescription pharmaceutical sales by molecule type ($m), 2002-14
    • Figure 18: Johnson & Johnson prescription pharmaceutical sales by source ($m), 2002-14
    • Figure 19: Johnson & Johnson operating revenue/cost analysis ($m), 2002-14